ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Rheumatoid arthritis (RA)"

  • Abstract Number: L11 • ACR Convergence 2021

    Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study

    ELVIRA D'ANDREA1, Rishi Desai2, Mengdong He3, Robert Glynn4, Hemin Lee2, Michael Weinblatt2, Daniel Solomon5 and Seoyoung Kim2, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
  • Abstract Number: L10 • ACR Convergence 2021

    A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

    joshua solomon1, Felix Woodhead2, Sonye Danoff3, Shana Haynes-Harp4, Tanvi Naik5, Cathie Spino5, Shelley Hurwitz6, Rie Maurer6, Daniel Chambers7, Martin Kolb8, Hiliary Goldberg6 and Ivan Rosas4, 1National Jewish Health, Denver, CO, 2University of Leicester, Leicester, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4Baylor College of Medicine, Houston, TX, 5University of Michigan, Ann Arbor, MI, 6Brigham and Womens Hospital, Boston, MA, 7University of Queensland, Brisbane, Australia, 8McMaster University, Hamilton, ON, Canada

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
  • Abstract Number: L02 • ACR Convergence 2021

    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases

    Ines Colmegna1, Mariana Useche1, Emmanouil Rampakakis2, Nathalie Amiable3, Emmanuelle Rollet-Labelle3, Louis Bessette4, Jo-Anne Costa4, Marc Dionne4, Mary-Ann Fitzcharles2, Elizabeth Hazel2, Deirdre McCormack2, Laetitia Michou4, Pantelis Panopalis2, Marc-Andre Langlois5, Sasha Bernatsky6 and Paul R. Fortin7, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Centre de Recherche du CHU de Quebec, Quebec, Canada, 4Universite Laval, Quebec, QC, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6McGill University, Montreal, QC, Canada, 7CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
  • Abstract Number: L01 • ACR Convergence 2021

    Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases

    Catherine Raptis1, Diego Andrey2, Christoph Berger3, Axel Finckh2, Pierre Lescuyer2, Adrian Ciurea4, Tanja Maletic1, Christos Polysopoulos1, Myriam Riek1, Almut Scherer1, Kim Lauper2, Burkhard Moeller5, Judith Safford6, Sandra Schweizer7, Isabell von Loga1, Nicolas Vuilleumier8 and Andrea Rubbert-Roth9, 1SCQM Foundation, Zurich, Switzerland, 2Geneva University Hospital, Geneva, Switzerland, 3University Hospital Basel, Basel, Switzerland, 4University Hospital Zurich, Zrich, Switzerland, 5Inselspital - University Hospital Bern, Bern, Switzerland, 6RheumaCura Foundation, Zurich, Switzerland, 7Swiss League Against Rheumatism, Zurich, Switzerland, 8University Hospital of Geneva, Geneva, Switzerland, 9Kantonspital St Gallen, St.Gallen, Switzerland

    Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy-  following vaccination with mRNA COVID-19 vaccines but long-term data…
  • Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium

    Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones

    Margaret Chang1, Anais Levescot 2, Nathan Nelson-Maney 3, Rachel Blaustein 4, Kellen Winden 1, Allyn Morris 4, Spoorthi Balu 4, Alexandra Wactor 4, Kevin Wei 5, Lauren Henderson 6, Rachael Clark 4, Deepak Rao 4, Robert Fuhlbrigge 7 and Peter Nigrovic 8, 1Boston Children's Hospital, Boston, 2Boston, 3, 4Brigham and Women's Hospital, Boston, 5BWH, Boston, 6Boston Children's Hospital, Watertown, Massachusetts, 7University of Colorado, Aurora, 8Boston Children's Hospital, Boston, Massachusetts

    Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…
  • Abstract Number: L02 • 2019 ACR/ARP Annual Meeting

    Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

    Naizhuo Zhao 1, Audrey Smargiassi 2, Marianne Hatzopoulou 3, Ines Colmegna 4, Marie Hudson 5, Marvin Fritzler 6, Philip Awadalla 7 and Sasha Bernatsky8, 1Research Institute of the McGill University Health Centre, Montreal, Canada, 2University of Montreal, Montreal, Canada, 3University of Toronto, Toronto, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, Canada, 7Ontario Institute for Cancer Research, Toronto, Canada, 8Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
  • Abstract Number: L12 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

    Evgeniy Nasonov 1, Saeed Fatenejad 2, Elena Korneva 3, Diana Krechikova 4, Alexey Maslyansky 5, Tatyana Plaksina 6, Marina Stanislav 7, Rumen Stoilov 8, Tamara Tyabut 9, Sergey Yakushin 10, Elena Zonova 11 and Mark Genovese12, 1FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, 2SFC Medica, Charlotte, North Carolina, 3R-Pharm, Moscow, Russia, 4Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, 5SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, 6SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, 7V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 8UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, 9Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, 10Ryazan State Medical University, Ryazan, Russia, 11Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, 12Stanford University, Stanford, CA

    Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
  • Abstract Number: 42 • 2019 ACR/ARP Annual Meeting

    Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis

    Sheila Arvikar1, Hatice Hasturk 2, Klemen Strle 1, Marcy Bolster 1, Deborah Collier 1, Alpdogan Kantarci 2 and Allen Steere 1, 1Massachusetts General Hospital, Boston, MA, 2Forsyth, Cambridge, MA

    Background/Purpose: Periodontitis and immune responses to periodontal pathogens such as Porphyromonas gingivalis (Pg) are associated with rheumatoid arthritis (RA) but the mechanisms underlying these connections…
  • Abstract Number: 177 • 2019 ACR/ARP Annual Meeting

    Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal

    Mariana Luís1, Salomé Garcia 2, Francisca Guimarães 3, Manuel António 4, Ana Fernandes 5, Filipe Araújo 6, Rita Cunha 7, Maura Couto 8, Ana Pinto 9, Lígia Silva 10, Margarida Cruz 11, Jose Pereira da Silva 12 and Catia Duarte 13, 1Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 2Centro Hospitalar São João, Porto, Portugal, 3Centro Hospitalar do Alto Minho, Ponte de Lima, Portugal, 4Centro Hospitalar Lisboa Norte, Lisboa, Portugal, 5Centro Hospitalar do Algarve, Faro, Portugal, 6Hospital Ortopédico de Sant’Ana, Lisboa, Portugal, 7Centro Hospitalar Baixo Vouga, Aveiro, Portugal, 8Centro Hospitalar Tondela-Viseu, Viseu, Portugal, 9Unidade Local de Saúde da Guarda, Guarda, Portugal, 10Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, 11Centro Hospitalar do Oeste, Caldas da Rainha, Portugal, 12Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, 13Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal

    Background/Purpose: Work disability is a common consequence of Rheumatoid Arthritis (RA) with economic implications for both the patient and society. Scarce information is available on…
  • Abstract Number: 248 • 2019 ACR/ARP Annual Meeting

    Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel

    Caroline Swift 1, Yvonne Viteri2, Gail Bridges 3, Mary Dorholt 4 and Monal Kohli 5, 1Express Scripts, St. Louis, MO, 2Accredo, Northvale, NJ, 3Accredo, Memphis, TN, 4Accredo, Maple Grove, MN, 5Express Scripts, Franklin Lakes, NJ

    Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
  • Abstract Number: 419 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

    Panagiotis Athanassiou 1, Ioannis Kallitsakis 2, Gkikas Katsifis 3, Anastasios Kotrotsios 4, Georgios Vosvotekas 5, Panagiotis Georgiou 6, Andreas Bounas 7, Yiannis Haratsis 8, Evangelia Petrikkou 8 and Dimitrios Vassilopoulos9, 1General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, 2Private Practice, Chania, Greece, 3Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, 4Private Practice, Karditsa, Greece, 5Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, 6General Hospital of Patras “Agios Andreas”, Patras, Greece, 7Olympion therapeutirion, Patras, Greece, 8Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, 92nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece

    Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
  • Abstract Number: 462 • 2019 ACR/ARP Annual Meeting

    The Endogenous Plasma Small RNAome of Rheumatoid Arthritis

    Michelle Ormseth1, Joseph Solus 2, Quanhu Sheng 2, Fei Ye 2, Haocan Song 2, Qiong Wu 2, Yan Guo 3, Annette Oeser 2, Ryan Allen 2, Kasey Vickers 2 and C. Michael Stein 2, 1Vanderbilt University Medical Center and Veterans Administration: TN Valley Healthcare System, Nashville, 2Vanderbilt University Medical Center, Nashville, 3University of New Mexico, Albuquerque

    Background/Purpose: Small RNA (sRNA) sequencing has revealed new classes of sRNAs beyond microRNAs. These sRNAs can regulate genes and are also useful biomarkers of disease.…
  • Abstract Number: 498 • 2019 ACR/ARP Annual Meeting

    Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?

    Barbara Mascialino1 and Teresa Tarrant 2, 1Thermo Fisher Scientific, Uppsala, Uppsala Lan, Sweden, 2Duke School of Medicine, Division of Rheumatology and Immunology, Durham, NC

    Background/Purpose: The 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis (RA) are based on a combination of clinical, laboratory, and imaging investigations. Positive serology contributes to…
  • Abstract Number: 545 • 2019 ACR/ARP Annual Meeting

    Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study

    Samantha Lent 1, Thierry Sornasse 2, Robert Georgantas 1, Jeremy Sokolove 2 and Iain McInnes3, 1AbbVie, Inc., North Chicago, IL, 2AbbVie Immunology Clinical Development, Redwood City, 3Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response to conventional…
  • Abstract Number: 847 • 2019 ACR/ARP Annual Meeting

    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

    Mark Genovese1, Josef Smolen 2, Tsutomu Takeuchi 3, Gerd Burmester 4, Dennis Brinker 5, Terence Rooney 5, Jinglin Zhong 6, Daojun Mo 5, Chadi Saifan 5, Anabela Cardoso 5, Maher Issa 5, Wen-Shuo Wu 5 and Kevin Winthrop 7, 1Stanford University, Stanford, CA, 2Medical University of Vienna, Vienna, Austria, 3Keio University School of Medicine, Tokyo, Japan, 4Charité—University Medicine Berlin, Berlin, Germany, 5Eli Lilly and Company, Indianapolis, IN, 6IQVIA, Morrisville, NC, 7Oregon Health and Science University, Portland, OR

    Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
  • 1
  • 2
  • 3
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences